Marker Therapeutics Inc Share Price Today: Live Updates & Key Insights

Marker Therapeutics Inc share price today is $1.32, up 1.52%. The stock opened at $1.29 against the previous close of $1.32, with an intraday high of $1.38 and low of $1.29.

Marker Therapeutics Inc Share Price Chart

Marker Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Marker Therapeutics Inc Share Price Performance

$1.32 0.0152(1.52%) MRKR at 23 Mar 2026 02:20 PM Biotechnology
Lowest Today 1.29
Highest Today 1.38
Today’s Open 1.29
Prev. Close 1.32
52 Week High 2.46
52 Week Low 0.81
Day’s Range: Low 1.29 High 1.38
52-Week Range: Low 0.81 High 2.46
1 day return -
1 Week return -5.63
1 month return -8.84
3 month return -5.63
6 month return +48.77
1 year return +8.94
3 year return +11.66
5 year return -95.31
10 year return -

Marker Therapeutics Inc Institutional Holdings

NEA Management Company, LLC 9.75

Blue Owl Capital Holdings LP 3.32

Vanguard Group Inc 2.08

Aisling Capital Management LP 1.95

Vanguard Total Stock Mkt Idx Inv 1.57

Goss Wealth Management LLC 0.89

Geode Capital Management, LLC 0.78

Renaissance Technologies Corp 0.74

Two Sigma Investments LLC 0.59

Vanguard Institutional Extnd Mkt Idx Tr 0.57

Advisor Group Holdings, Inc. 0.57

LPL Financial Corp 0.50

Fidelity Extended Market Index 0.46

Citadel Advisors Llc 0.35

Jane Street Group LLC 0.24

Boyer Financial Services, Inc. 0.22

Virtu Financial LLC 0.17

Invst LLC 0.16

XTX Topco Ltd 0.13

State Street Corp 0.13

NT Ext Equity Mkt Idx Fd - L 0.12

Creative Planning Inc 0.10

Matrix Asset Advisors Inc 0.09

HRT FINANCIAL LLC 0.08

Spartan Extended Market Index Pool F 0.08

Fidelity Series Total Market Index 0.08

Fidelity Total Market Index 0.08

Spartan Total Market Index Pool G 0.06

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.05

NT Ext Equity Mkt Idx Fd - NL 0.03

Fidelity Nasdaq Composite Index 0.03

Northern Trust Extended Eq Market Idx 0.03

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

Vanguard Instl Ttl Stck Mkt Idx Tr 0.02

Vanguard U.S. Eq Idx £ Acc 0.02

State St US Extended Mkt Indx NL Cl C 0.01

BNYM Mellon SL Market Completion UC1 0.01

SSgA U.S. Total Market Index Strategy 0.01

Northern Trust Wilshire 5000 0.00

NT US Market Cap Idx Fd - L 0.00

Marker Therapeutics Inc Market Status

Strong Buy: 2

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Marker Therapeutics Inc Fundamentals

Market Cap 17.34 M

PB Ratio 1.215

PE Ratio 0.0

Enterprise Value 4.75 M

Total Assets 19070997.00 M

Volume 131457

Marker Therapeutics Inc Company Financials

Annual Revenue FY23:9013544 9.0M, FY22:9004530 9.0M, FY21:1241710 1.2M, FY20:466785 0.5M, FY19:213194 0.2M

Annual Profit FY23:null 0.0M, FY22:9004530 9.0M, FY21:1241710 1.2M, FY20:466785 0.5M, FY19:213194 0.2M

Annual Net worth FY23:-9290163 -9.3M, FY22:-29915605 -29.9M, FY21:-41873171 -41.9M, FY20:-28526328 -28.5M, FY19:-20327122 -20.3M

Quarterly Revenue Q3/2025:1232938 1.2M, Q2/2025:861184 0.9M, Q1/2025:349104 0.3M, Q3/2024:1926020 1.9M, Q2/2024:1169236 1.2M

Quarterly Profit Q3/2025:1232938 1.2M, Q2/2025:-3315870 -3.3M, Q1/2025:-2786323 -2.8M, Q3/2024:1926020 1.9M, Q2/2024:1169236 1.2M

Quarterly Net worth Q3/2025:-1998662 -2.0M, Q2/2025:-4015564 -4.0M, Q1/2025:-4446184 -4.4M, Q3/2024:-2308192 -2.3M, Q2/2024:-2192677 -2.2M

About Marker Therapeutics Inc & investment objective

Company Information Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.

Organisation Biotechnology

Employees 5

Industry Biotechnology

CEO Dr. Juan F. Vera M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Marker Therapeutics Inc FAQs

What is the share price of Marker Therapeutics Inc today?

The current share price of Marker Therapeutics Inc is $1.32.

Can I buy Marker Therapeutics Inc shares in India?

Yes, Indian investors can buy Marker Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Marker Therapeutics Inc shares in India?

You can easily invest in Marker Therapeutics Inc shares from India by:

Can I buy fractional shares of Marker Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Marker Therapeutics Inc?

Marker Therapeutics Inc has a market cap of $17.34 M.

In which sector does Marker Therapeutics Inc belong?

Marker Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Marker Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Marker Therapeutics Inc?

The PE ratio of Marker Therapeutics Inc is N/A and the PB ratio is 1.22.